Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas. by de Foy, K. A. et al.
British Joumal ofCancer(1998) 77(10), 1642-1644
© 1998 Cancer Research Campaign
Mutation analysis of the c-mos proto-oncogene in
human ovarian teratomas
KAF de Foy', SA Gaytherl, WH Colledge2, S Crockett3, IV Scott3, MJ Evans4 and BAJ Ponder'
'CRC Human Cancer Genetics Research Group, Box 238, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK; 2Physiological Laboratory,
University of Cambridge, Downing Street, Cambridge CB2 3EG, UK; 3Department of Obstetrics and Gynaecology, Derby City General Hospital, Uttoxeter Road,
Derby DE22 3NE, UK; 4Wellcome CRC Institute and Department of Genetics, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, UK
Summary Female transgenic mice lacking a functional c-mos proto-oncogene develop ovarian teratomas, indicating that c-mos may behave
as a tumour-suppressor gene for this type of tumour. We have analysed the entire coding region of the c-MOS gene in a series of human
ovarian teratomas to determine whether there are any cancer-causing alterations. DNA from twenty teratomas was analysed by single-strand
conformational analysis (SSCA) and heteroduplex analysis (HA) to screen for somatic and germline mutations. In nine of these tumours the
entire gene was also sequenced. A previously reported polymorphism and a single new sequence variant were identified, neither of which we
would predict to be disease-causing alterations. These results suggest that mutations in the coding region of the c-MOS gene do not play a
significant role in the genesis of human ovarian teratomas.
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The mos gene was first identified as the oncogenic element of the
murine Moloney sarcoma virus (Moloney, 1966). Overexpression
of the gene causes transformation of NIH 3T3 cells and tumour
growth in mice (Fefer et al, 1967; Blair et al, 1981). However, few
studies have implicated c-MOS in human oncogenesis (Parkar et
al, 1988; Stenman et al, 1991). The human c-MOS gene, located
on chromosome 8q11, consists of a single 1.2-kb exon encoding a
serine-threonine kinase (Watson et al, 1982). The MOS protein is
the active component ofcytostatic factor (CSF) that is responsible
for arresting developing oocytes in metaphase II (Sagata et al,
1989; Lorca et al, 1991).
Two studies using knock-out mice provide evidence for a role
for c-mos in the genesis ofovarian teratomas (Colledge et al, 1994;
Hashimoto et al, 1994). In both studies, male mutants were pheno-
typically normal, but female mutant mice exhibited a significantly
reduced fertility as well as an elevated risk of developing ovarian
teratomas. The females' reduced fertility was attributed to the fact
that large numbers of their oocytes failed to arrest in metaphase II
and became parthenogenetically activated. Genetic studies of
mouse and human ovarian teratomas suggest that both arise from
the development ofparthenogenetically activated oocytes (Stevens
and Varnum, 1974; Surti et al, 1990).
We have examined the c-MOS gene in a set of twenty human
ovarian teratomas using single-strand conformational analysis
(SSCA) and heteroduplex analysis (HA). The entire gene was also
sequenced in nine of these tumours to ensure that mutations were
not being missed. A previously reported polymorphism and a
unique silent base change were found.
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MATERIALS AND METHODS
Tumour material
DNA was prepared from 12 frozen and eight paraffin-embedded
ovarian tumours classified as teratomas by histological examina-
tion. Frozen tumours were ground in liquid nitrogen and homo-
genized in 3 ml ofTNE (0.5 M Tris pH 8.0, 0.1 M sodium chloride,
20 mm EDTA). Sodium dodecyl sulphate (SDS) was added to a
final concentration of 1%, and the solution was treated with
Proteinase K (2 mg ml-) at 55°C overnight. DNA was extracted
with phenol-chloroform and ethanol precipitated. Paraffin-
embedded tissue was scraped from slides into 200 gl of extraction
buffer (1 x PCR buffer, 1.5 mm magnesium chloride, 0.45%
Tween-20 and 0.45% NP-40) and treated with proteinase K
(200 mg ml-') for 3 h at 55°C.
SSCA/HA
The c-MOS gene was PCR amplified with Red Hot DNA
Polymerase (Advanced Biotechnologies) in five overlapping
fragments of approximately 250-300 bp, using the following
primer pairs: Hu MOS IF (5'-TCTTCATTCACTCCAGCGG-3')
and Hu MOS IR (5'-AAGTCGCCT7GTACACCGAG-3');
Hu MOS 2F (5'-GGTGTGCTTGCTGCAGAG-3') and Hu
MOS 2R (5'-CGCCATAGATGACTTGGTGT-3'); Hu MOS 3F
(5'-CCTAGGGACCATCATCATGG-3') and Hu MOS 3R
(5'-GTGTCTGGAAGCACAGCAGA-3'); Hu MOS 4F (5'-TC-
AGTGAGCAGGATGTCTGTAA-3') and Hu MOS 4R (5'-GGA-
CGGGCGCAGGTCGTAGGCCAC-3'); and Hu MOS SF
(5'-CTTGACCAAGThTTCAGTCAGC-3') and Hu MOS SR
(5'-CTTGACCAAGTTTTCAGTCAGC-3'). SSCA/HA was
performed as previously described (Gayther et al, 1995). PCR
products were denatured at 99°C for 10min in the presence of





Figure 1 (A) SSCA patterns produced by the G to T polymorphism at
nucleotide 553 in fragment Hu MOS 2: homozygous for the rare allele (TT),
homozygous for the common allele (GG) and heterozygous (GT). (B-C)
Normal (N) patterns of fragment HU MOS 4 next to variant (V) patterns
produced by teratoma 3T on (B) SSCA and (C) HA gels. The variant patterns
are due to a silent C to A substitution at nucleotide 1020
formamide, then left on ice for 10 min to allow some of the product
to form homo- and heteroduplexes. SSCA and HA fragments were
resolved on the same gel. Electrophoresis was performed using 0.8%
MDE (JT Baker) polyacrylamide gels with and without 10%
glycerol. Gels were silver-stained as described previously (Gayther
et al, 1995).
Sequence analysis
Nine frozen teratomas with abundant DNA were selected for
sequence analysis. DNA was PCR amplified with the primers
described above. PCR products were purified from 2% low-
melting-point agarose gels using the Wizard PCR system
(Promega). Sequencing reactions were performed using the Exo(-)
Pfu Cyclist DNA Sequencing kit (Stratagene) with [33P]dATP as a
label. The sequencing products were run for both 2 and 4 h at 65 W
on 6% polyacrylamide gels (Sequagel-6, Flowgen). All PCR prod-
ucts were sequenced in both the forward and reverse directions.
RESULTS
Six of the twenty samples revealed similar variant SSCA patterns
with the Hu MOS 2 primers (Figure IA). Sequence analysis
showed this was due to a previously reported polymorphism (G to
T transversion) at codon 105 (Eng et al, 1996). This polymorphism
was present in our set ofteratomas at the same frequency as it was
reported in the overall population. A seventh sample showed vari-
ation in both SSCA and HA patterns with the Hu MOS 4 primers
(Figure lB and C). Sequencing revealed a silent C to A transver-
sion at codon 260 in this tumour. The blood from this patient was
not available to test whether this base change was somatic or
germline. However, as it does not cause an amino acid change, we
would predict that it does not affect the function of c-MOS. No
further base substitutions were identified by sequencing the entire
coding region in DNA from nine ofthe frozen teratomas.
DISCUSSION
Although c-mnos has been shown to be oncogenic in some
mammals and mammalian cell lines, a role for this gene in human
tumour formation has remained elusive. Given the strong experi-
mental evidence suggesting a role for c-mos as a tumour-
suppressor gene in murine ovarian teratomas, the absence of
mutations in this analysis is perhaps surprising. It is possible that
MOS is involved in human teratomas not through coding muta-
tions but by genetic alterations outside the c-MOS coding region
that alter expression of the gene, or through mutations affecting
other members of its signalling pathway. Loss of heterozygosity
analysis of the c-MOS region would be complicated by the fact
that the majority of ovarian teratomas arise from a failure of
meiosis II and contain two almost identical sets of chromosomes
(Surti et al, 1990).
The lack of mutations in human teratomas might also be
explained by species-specific differences. The histological profile
of ovarian teratomas appears to be similar between human and
mouse tumours (Michael and Roth, 1993; Furuta et al, 1995).
However, there is evidence that the mos protein plays different
roles in different species. In Xenopus oocyte maturation, mos is
required for the activation of maturation promoting factor,
germinal vesicle breakdown and the extrusion of the first polar
body, as well as being the active component of cytostatic factor
(Sagata et al, 1988; Yew et al, 1993). In contrast, the phenotype of
c-mos mutant mice suggests that murine mos is only needed to
arrest developing oocytes in metaphase II (Colledge et al, 1994;
Hashimoto et al, 1994). Perhaps the functions ofhuman c-MOS do
not render it as vulnerable a target for cancer induction as the
murine version ofthe gene seems to be.
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